Daewoong Pharmaceutical Co., Ltd (KRX:069620)
South Korea flag South Korea · Delayed Price · Currency is KRW
119,500
-1,600 (-1.32%)
At close: Jun 8, 2026

Daewoong Pharmaceutical Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
199,862195,85624,735121,73942,24024,506
Depreciation & Amortization
54,99951,07248,97843,79739,69540,883
Loss (Gain) From Sale of Assets
-52,281-52,328465.97-30,198-246.41,029
Asset Writedown & Restructuring Costs
12,83014,65415,4922,3725,2192,109
Loss (Gain) From Sale of Investments
-17,6774,50624,951-130.674,112-8,308
Loss (Gain) on Equity Investments
14,2336,10723,1531,443374.54-257.52
Stock-Based Compensation
-337.18475.96545.311,6181,8412,005
Provision & Write-off of Bad Debts
4,1833,0572,1925,8352,2502,125
Other Operating Activities
5,718272.54-6,22610,254-8,8525,813
Change in Accounts Receivable
-8,210-8,563-22,597-478.7-23,193-20,692
Change in Accounts Payable
10,20823,294-16,67416,59712,408-8,373
Change in Other Net Operating Assets
-60,194-89,199-43,523-36,83842,368-844.34
Operating Cash Flow
163,334149,20551,492136,009118,21539,994
Operating Cash Flow Growth
323.90%189.76%-62.14%15.05%195.58%-60.39%
Capital Expenditures
-245,620-191,534-155,145-109,338-65,227-29,088
Sale of Property, Plant & Equipment
612.95455.143.051,446483.47257.43
Cash Acquisitions
-2,928-2,928--5,807--
Divestitures
---45.59--
Sale (Purchase) of Intangibles
-59,911-49,478-73,858-46,289-46,826-45,633
Investment in Securities
-9,586-3,928-35,557-8,7916,983-13,220
Other Investing Activities
178.53178.53-636.343,12367.5-
Investing Cash Flow
-316,054-247,026-265,451-165,621-106,872-87,683
Short-Term Debt Issued
-377,97180,000113,74286,15452,352
Long-Term Debt Issued
-310,548325,18765,000149,683108,357
Total Debt Issued
668,060688,519405,187178,742235,837160,709
Short-Term Debt Repaid
--513,468-106,264-87,934-1,212-53,258
Long-Term Debt Repaid
--2,290-92,263-94,201-201,593-91,675
Total Debt Repaid
-441,368-515,758-198,527-182,136-202,805-144,933
Net Debt Issued (Repaid)
226,692172,761206,660-3,39433,03215,776
Issuance of Common Stock
---49,890-40,249
Dividends Paid
-9,053-8,075-7,741-7,278-8,066-6,458
Other Financing Activities
-1,348-334.231,702-0-9,450656.41
Financing Cash Flow
216,291164,352200,62139,21815,51750,224
Foreign Exchange Rate Adjustments
2,310-539.934,782-1,052184.471,073
Miscellaneous Cash Flow Adjustments
0-0-0--
Net Cash Flow
65,88165,991-8,5568,55527,0443,608
Free Cash Flow
-82,286-42,329-103,65326,67152,98810,906
Free Cash Flow Growth
----49.67%385.84%-85.36%
Free Cash Flow Margin
-5.17%-2.70%-7.29%1.94%4.14%0.95%
Free Cash Flow Per Share
-7151.19-3678.75-9008.372334.474786.97991.08
Cash Interest Paid
20,41223,61523,08416,60411,4809,839
Cash Income Tax Paid
16,52214,54838,9018,3919,0505,500
Levered Free Cash Flow
-153,676-98,628-174,863-18,388-44,86444,982
Unlevered Free Cash Flow
-145,994-90,831-170,496-9,886-39,61051,387
Change in Working Capital
-58,195-74,468-82,794-20,72031,583-29,910